Small-molecule-induced ERBB4 activation to treat heart failure
Abstract Heart failure is a common and deadly disease requiring new treatments. The neuregulin-1/ERBB4 pathway offers cardioprotective benefits, but using recombinant neuregulin-1 as therapy has limitations due to the need for intravenous delivery and lack of receptor specificity. We hypothesize tha...
Saved in:
| Main Authors: | Julie M. T. Cools, Bo K. Goovaerts, Eline Feyen, Siel Van den Bogaert, Yile Fu, Céline Civati, Jens Van fraeyenhove, Michiel R. L. Tubeeckx, Jasper Ott, Long Nguyen, Eike M. Wülfers, Benji Van Berlo, Antoine A. F. De Vries, Nele Vandersickel, Daniël A. Pijnappels, Dominique Audenaert, H. Llewelyn Roderick, Hans De Winter, Gilles W. De Keulenaer, Vincent F. M. Segers |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-024-54908-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ERBB4 confers metastatic capacity in Ewing sarcoma
by: Ariadna Mendoza‐Naranjo, et al.
Published: (2013-05-01) -
DGM-TOP: automatic identification of the critical boundaries in atrial tachycardia
by: Robin Van Den Abeele, et al.
Published: (2025-05-01) -
Prefrontal ErbB4-positive interneurons for avoidance
by: Wanpeng Cui, et al.
Published: (2025-05-01) -
Impact of NSAIDs and endurance exercise on myocardial fibrosis and arrhythmogenesis in murine coxsackieviral myocarditis
by: Sander Eens, et al.
Published: (2025-08-01) -
Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status.
by: Gillian Farnie, et al.
Published: (2013-01-01)